Quick Asked: Vistagen Therapeutics Contact Us?
Last update: 04 May, 2024 
97 Views
Listing Results Vistagen Therapeutics Contact Us? Question Answers
VistaGen Therapeutics Receives FDA Fast Track Designation
+1 (650) 577-3600 Company Contact Mark A. McPartland VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@ vistagen.com Investor Contact: Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: VistaGen@KCSA.com. Source: VistaGen Therapeutics, Inc. Released January 3, 2018
Contact Us VistaGen Therapeutics, Inc
(650) 577-3600 Contact Us. Contact Us Please feel free to reach out to us. We're happy to hear from you and answer any questions regarding our company and our products. VistaGen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Tel: (650) 577-3600 Fax: (888) 482-2602 Email: info@ vistagen.com.
FAQ :: VistaGen Therapeutics, Inc. (VTGN)
800-368-5948 343 Allerton Avenue South San Francisco, CA 94080 When is VistaGen Therapeutics, Inc.'s fiscal year end? March 31st Who is VistaGen Therapeutics, Inc.'s transfer agent? Computershare, Inc. P.O. BOX 30170 College Station, TX 77842 T: 800-368-5948 www-us.computershare.com Who is VistaGen Therapeutics, Inc.'s independent auditor?
VistaGen Therapeutics, Inc. (VTGN) Company Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
Jobs with VistaGen Therapeutics, Inc. BioSpace
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2. 9/13/2021. VistaGen Therapeutics, Inc. announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of PH94B for the acute treatment of anxiety in ...
About :: VistaGen Therapeutics, Inc. (VTGN)
About. VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders.
VistaGen Therapeutics Company Profile Office Locations
VistaGen Therapeutics has 9 employees at their 1 location. See insights on VistaGen Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.
VistaGen Therapeutics, Inc. Home Facebook
VistaGen Therapeutics, Inc. August 12 at 1:30 PM ·. Today at 5:00 pm ET, VistaGen's management team will host a conference call to discuss its financial and operating results for its fiscal year 2022 first quarter ended June 30, 2021 and provide a business update. For the live webcast visit: viavid.webcasts.com.
VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of
(650) 577-3606 Contact Us . Contact Us VistaGen Therapeutics Phone: (650) 577-3606 Email: IR@ vistagen.com. Recommended Stories. Insider Monkey. Warren Buffett is Selling These 10 Stocks.
VistaGen Therapeutics Crunchbase Company Profile & ...
Contact Email [email protected] Phone Number 6505589566 VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS).
VistaGen Therapeutics Announces Pricing of Underwritten
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of ...
Home VistaGen Therapeutics, Inc
About Us Committed to developing a new generation of medicines that go beyond the current standard of care. VistaGen Therapeutics is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS ...
Investor Relations :: VistaGen Therapeutics, Inc. (VTGN)
VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's CNS drug candidates, PH94B, PH10, and AV-101, has a
Vistagen Therapeutics, Inc. Company Profile South San
Company Description: Vistagen Therapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Vistagen Therapeutics, Inc. has 9 total employees across all of its ...